Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?  

作　　者：Christian Humpel 

机构地区：[1]Laboratory of Psychiatry and Experimental Alzheimer’s Research,Medical University of Innsbruck,Innsbruck,Austria

出　　处：《Neural Regeneration Research》2022年第9期1881-1884,共4页中国神经再生研究（英文版）

摘　　要：Neurodegenerative brain disorders are a major burden in our society,such as Alzheimer´s disease.In order to repair or prevent such diseases,drugs are designed which enter the brain,but the blood-brain barrier limits their entry and the search for alternative pathways is important.Recently,we reported that intranasal delivery of the amyloid-beta degrading enzyme neprilysin eliminated amyloid-beta plaques in transgenic Alzheimer´s disease mice.This review describes the anatomical structure of the intranasal pathway,explains the intranasal delivery of pure neprilysin,cell-loaded neprilysin(platelets)and collagen-embedded neprilysin to destruct amyloid-beta plaques in Alzheimer´s disease in transgenic APP_SweDI mice and hypothesizes why this may cause compensation and why the amyloid-beta cascade hypothesis may fail.

关 键 词：AMYLOID-BETA amyloid-beta degrading enzyme clear plaque collagen biomaterial INTRANASAL NEPRILYSIN nose-to-brain 

分 类 号：R749.16[医药卫生—神经病学与精神病学]